CA2681639A1 - Compounds and methods for treatment of disorders associated with er stress - Google Patents

Compounds and methods for treatment of disorders associated with er stress Download PDF

Info

Publication number
CA2681639A1
CA2681639A1 CA002681639A CA2681639A CA2681639A1 CA 2681639 A1 CA2681639 A1 CA 2681639A1 CA 002681639 A CA002681639 A CA 002681639A CA 2681639 A CA2681639 A CA 2681639A CA 2681639 A1 CA2681639 A1 CA 2681639A1
Authority
CA
Canada
Prior art keywords
independently
lower alkyl
substituted
occurrence
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002681639A
Other languages
English (en)
French (fr)
Inventor
Teoman Uysal
Nicholas D.P. Cosford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNDEXA PHARMACEUTICALS CORP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2681639A1 publication Critical patent/CA2681639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002681639A 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress Abandoned CA2681639A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US78533506P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US78532806P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US78533806P 2006-03-22 2006-03-22
US78518206P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US60/785,182 2006-03-22
US60/785,035 2006-03-22
US60/785,235 2006-03-22
US60/785,335 2006-03-22
US60/785,154 2006-03-22
US60/785,338 2006-03-22
US60/785,007 2006-03-22
US60/785,185 2006-03-22
US60/785,328 2006-03-22
US60/785,034 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (1)

Publication Number Publication Date
CA2681639A1 true CA2681639A1 (en) 2007-10-04

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002681639A Abandoned CA2681639A1 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Country Status (6)

Country Link
US (1) US20090131384A1 (https=)
EP (1) EP2001897A2 (https=)
JP (1) JP2009530399A (https=)
AU (1) AU2007230991A1 (https=)
CA (1) CA2681639A1 (https=)
WO (1) WO2007111994A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005027A (es) 2004-10-26 2007-06-19 Dolby Lab Licensing Corp Calculo y ajuste de la sonoridad percibida y/o el balance espectral percibido de una senal de audio.
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
JP5620392B2 (ja) * 2008-11-03 2014-11-05 タフツ ユニヴァーシティーＴｕｆｔｓ Ｕｎｉｖｅｒｓｉｔｙ クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL2519100T3 (pl) 2009-12-29 2017-09-29 Mapi Pharma Limited Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3501520A1 (en) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
US9084826B2 (en) 2012-05-01 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists; compositions and method of uses
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
JP6422452B2 (ja) 2013-03-14 2018-11-14 ユニバーシティ オブ マカオＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｃａｕ ヤクチ（益智（ａｌｐｉｎｉａｅｏｘｙｐｈｙｌｌａｅｆｒｕｃｔｕｓ））およびその全合成から単離される新規な抗神経変性天然化合物
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
WO2016073767A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
DE102017005884A1 (de) * 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
CA3058754A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
DE102018004733A1 (de) * 2018-06-14 2019-12-19 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
US20240391948A1 (en) * 2021-07-26 2024-11-28 Shaperon Inc. Novel compound that inhibits tnf-alpha generation and inflammasome activity and preparation method therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
WO2001076531A2 (en) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Also Published As

Publication number Publication date
US20090131384A1 (en) 2009-05-21
WO2007111994A3 (en) 2008-06-12
JP2009530399A (ja) 2009-08-27
WO2007111994A2 (en) 2007-10-04
AU2007230991A1 (en) 2007-10-04
EP2001897A2 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
CA2681639A1 (en) Compounds and methods for treatment of disorders associated with er stress
JP6101675B2 (ja) 代謝病の治療用の化合物
CN101605754B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的维生素a酸类和类维生素a酸化合物的前药
AU2007319848B2 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
TWI351395B (en) Large-scale synthesis of selective androgen recept
CN103096895B (zh) 烟酸模拟物及其使用的方法
TW200422041A (en) Method of treatment for sexual dysfunction
JP7383124B2 (ja) リモノイド化合物およびｄｐｐ－４阻害剤を含有する組合せ製品
WO2019029319A1 (zh) 包含柠檬苦素类化合物和双胍类化合物的组合产品
TW201336831A (zh) 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物
JP2022544299A (ja) リモノイド化合物およびチアゾリジンジオン化合物を含有する組合せ製品
IL307865A (en) Sgc stimulators
JP2009519946A (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
CN102532114B (zh) 烟酸衍生物,其制备方法及其药物组合物
TW202515549A (zh) 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN102659609A (zh) 非诺贝特酸盐及其制备方法和应用，以及其药物组合物
AU2013257710B2 (en) Compositions and methods for the treatment of neurological disorders
CN102659570B (zh) 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
JP2024041865A (ja) パ－キンソン病治療用の新規高透過薬物及びその組成物
WO2023160702A1 (zh) 氨基脂质化合物、其制备方法、组合物和应用
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
US20220119333A1 (en) Phenoxy acid compounds and medical uses thereof
US20130317034A1 (en) Combination therapy for treating diabetes
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
CN104892457A (zh) 一种异羟肟酸类衍生物、其药物组合物、制备方法及用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130322